Scopus Bio Pharma Inc. SCPS
We take great care to ensure that the data presented and summarized in this overview for Scopus BioPharma Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SCPS
View allLatest Institutional Activity in SCPS
Top Purchases
Top Sells
About SCPS
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.
Insider Transactions at SCPS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 27
2021
|
Ira Scott Greenspan Executive Committee Chairman |
BUY
Open market or private purchase
|
Indirect |
790
+5.12%
|
$3,160
$4.98 P/Share
|
|
Aug 27
2021
|
Ira Scott Greenspan Executive Committee Chairman |
BUY
Open market or private purchase
|
Direct |
110
+0.13%
|
$440
$4.92 P/Share
|
|
Aug 27
2021
|
Joshua R Lamstein Chairman |
BUY
Open market or private purchase
|
Direct |
200
+0.17%
|
$1,000
$5.0 P/Share
|
|
Aug 26
2021
|
Joshua R Lamstein Chairman |
BUY
Open market or private purchase
|
Direct |
200
+0.17%
|
$800
$4.9 P/Share
|
|
Aug 24
2021
|
Ira Scott Greenspan Executive Committee Chairman |
BUY
Open market or private purchase
|
Direct |
50
+0.06%
|
$200
$4.65 P/Share
|
|
Aug 23
2021
|
Ira Scott Greenspan Executive Committee Chairman |
BUY
Open market or private purchase
|
Direct |
500
+0.6%
|
$2,000
$4.41 P/Share
|
|
Aug 20
2021
|
Ira Scott Greenspan Executive Committee Chairman |
BUY
Open market or private purchase
|
Direct |
400
+0.49%
|
$1,600
$4.23 P/Share
|
|
Aug 19
2021
|
Ira Scott Greenspan Executive Committee Chairman |
BUY
Open market or private purchase
|
Indirect |
2,000
+12.62%
|
$8,000
$4.04 P/Share
|
|
Aug 19
2021
|
Joshua R Lamstein Chairman |
BUY
Open market or private purchase
|
Direct |
800
+0.66%
|
$3,200
$4.04 P/Share
|
|
Aug 18
2021
|
Ira Scott Greenspan Executive Committee Chairman |
BUY
Open market or private purchase
|
Indirect |
1,000
+7.78%
|
$4,000
$4.27 P/Share
|
|
Aug 17
2021
|
Ira Scott Greenspan Executive Committee Chairman |
BUY
Open market or private purchase
|
Indirect |
1,000
+8.44%
|
$4,000
$4.13 P/Share
|
|
Jul 27
2021
|
Ira Scott Greenspan Executive Committee Chairman |
BUY
Open market or private purchase
|
Direct |
200
+0.25%
|
$800
$4.54 P/Share
|
|
Jul 26
2021
|
Ira Scott Greenspan Executive Committee Chairman |
BUY
Open market or private purchase
|
Direct |
400
+0.49%
|
$1,600
$4.76 P/Share
|
|
Jul 26
2021
|
Ira Scott Greenspan Executive Committee Chairman |
BUY
Open market or private purchase
|
Indirect |
1,000
+9.22%
|
$4,000
$4.78 P/Share
|
|
Jul 23
2021
|
Joshua R Lamstein Chairman |
BUY
Open market or private purchase
|
Direct |
1,500
+1.25%
|
$6,000
$4.71 P/Share
|
|
Jul 23
2021
|
Ira Scott Greenspan Executive Committee Chairman |
BUY
Open market or private purchase
|
Indirect |
1,100
+11.06%
|
$4,400
$4.77 P/Share
|
|
Jun 01
2021
|
Paul Hopper Director |
BUY
Other acquisition or disposition
|
Direct |
6,333
+33.33%
|
-
|
|
Jun 01
2021
|
Paul Hopper Director |
BUY
Other acquisition or disposition
|
Indirect |
700,000
+33.33%
|
-
|
|
Feb 25
2021
|
Robert J Gibson Vice Chairman |
BUY
Open market or private purchase
|
Direct |
150
+33.33%
|
$1,350
$9.29 P/Share
|
|
Feb 25
2021
|
Ira Scott Greenspan Executive Committee Chairman |
BUY
Open market or private purchase
|
Indirect |
800
+9.36%
|
$7,200
$9.01 P/Share
|